Role of potassium excretion and percent body fat on ethnic differences in plasma aldosterone levels

Ethnicity and Disease

Volumn 16, Issue 3, 2006, Pages

  Jones, Jennifer ^a,c   Park, Jung Jun ^a   Dowling, Thomas ^b   Phares, Dana ^a   Park, Joon Young ^a   Brown, Michael ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

African Americans; K+ excretion; Plasma aldosterone

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; POTASSIUM; SODIUM;

ADULT; AFRICAN AMERICAN; AGED; ALDOSTERONE BLOOD LEVEL; BODY FAT; BORDERLINE HYPERTENSION; CAUCASIAN; CONFERENCE PAPER; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG DOSE REDUCTION; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM URINE LEVEL; PREHYPERTENSION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; ARTICLE; BLOOD; BODY MASS; COMPARATIVE STUDY; MIDDLE AGED; OBESITY; URINE;

ADIPOSITY; AFRICAN AMERICANS; AGED; ALDOSTERONE; BODY MASS INDEX; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; POTASSIUM; SODIUM;

EID: 34250650498     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269(39): 24316-24320.
2. Takeda R, Hatakeyama H, Takeda Y, et al. Aldosterone biosynthesis and action in vascular cells. Steroids. 1995;60(1):120-124.
3. Heymes C, Garnier A, Fuchs S, et al. Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects. Mol Cell Endocrinol. 2004;217(1-2):213-219.
4. Satoh M, Nakamura M, Saitoh H, et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond). 2002;102(4):381-386.
5. Struthers AD, Macdonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-670.
6. Bonvalet JP, Alfaidy N, Farman N, Lombes M. Aldosterone: intracellular receptors in human heart. Eur Heart J. 1995;16(suppl N): 92-97.
7. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41.
8. Katada J, Meguro T, Saito H, et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation. 2005;111: 2157-2164.
9. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109(18):2213-2220.
10. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98(4):1063-1068.
11. He FJ, Markandu ND, Sagnella GA, MacGregor GA. Importance of the renin system in determining blood pressure fall with salt restriction in Black and White hypertensives. Hypertension. 1998;32(5):820-824.
12. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin-angiotensin system and blood pressure: differences between Blacks and Whites. Am J Hypertens. 1999;12(6): 555-562.
13. Helmer OM, Judson WE. Metabolic studies on hypertensive patients with suppressed plasma renin activity not due to hyperaldosteronism. Circulation. 1968;38(5):965-976.
14. Pratt JH, Jones JJ, Millet JZ, Wagner MA, Fineberg NS. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med. 1989; 321(17):1152-1157.
15. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens. 2001;15(1):17-25.
16. Fisher ND, Gleason RE, Moore TJ, Williams GH, Hollenberg NK. Regulation of aldosterone secretion in hypertensive Blacks. Hypertension. 1994;23(2):179-184.
17. Langford HG, Cushman WC, Hsu H. Chronic effect of KCl on Black-White differences in plasma renin activity, aldosterone, and urinary electrolytes. Am J Hypertens. 1991;4(5, pt 1):399-403.
18. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998; 24(3-4):789-796.
19. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7(4):355-362.
20. Grim CE, Cowley AWJr, Hamet P, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension. 2005;45(4):766-772.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
22. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-2572.
23. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102(18):2284-2299.
24. Cartledge S, Lawson N. Aldosterone and renin measurements. Ann Clin Biochem. 2000;37 (pt 3):262-278.
25. Stewart PM. Mineralocorticoid hypertension. Lancet. 1999;353(9161):1341-1347.
26. Kley HK, Schlaghecke R, Kruskemper HL. Stability of steroids in plasma over a 10-year period. J Clin Chem Clin Biochem. 1985; 23(12):875-878.
27. Plouin PF, Chatellier G, Guyene TT, Vincent N, Corvol P. Recent advances in the clinical study of the renin system. Reference values and conditions of validity. Presse Med. 1989; 18(18):917-921.
28. Quest Diagnostics. 2005, available at http://cas2. questdiagnostics.com/scripts/webdos. wls?MGWLPN=QDCWS0212&wlapp= DOS&OrderCode=734X&SITE=18& SearchString=P%2A&tmradio=title.
29. Quest Diagnostics. 2005, available at http://cas2. questdiagnostics.com/scripts/webdos. wls?MGWLPN=QDCWS0212&wlapp= DOS&OrderCode=838X&SITE=18& SearchString=S%2A&tmradio=title.
30. Urinary and serum electrolytes in untreated Black and White hypertensives. Veterans Administration Cooperative Study Group on Antihypertensive Agents. J Chronic Dis. 1987; 40(9):839-847.
31. Suh A, DeJesus E, Rosner K, et al. Racial differences in potassium disposal. Kidney Int. 2004;66(3):1076-1081.
32. Luft FC, Miller JZ, Grim CE, et al. Salt sensitivity and resistance of blood pressure. Age and face as factors in physiological responses. Hypertension. 1991;17:1-102-1-108.
33. Luft FC, Rankin LI, Bloch R, et al. Cardiovascular and humoral responses to extremes of sodium intake in normal Black and White men. Circulation. 1979;60(3):697-706.
34. Jamerson KA. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis. 2000;36:S24-S30.
35. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002;20(5):965-973.
36. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43(2):358-363.
37. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese Black versus White adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab. 2003;88(6):2534-2540.
38. Kanaley JA, Giannopoulou I, Tillapaugh-Fay G, Nappi JS, Ploutz-Snyder LL. Racial differences in subcutaneous and visceral fat distribution in postmenopausal Black and White women. Metabolism. 2003;52(2): 186-191.
39. Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African Americans. Trandolapril Multicenter Study Group. J Hum Hypertens. 1998;12(3): 189-194.
40. Weir MR, Smith DH, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001;14(7, pt 1):665-671.
41. Pratt JH, Rebhun JF, Zhou L, et al. Levels of mineralocorticoids in Whites and Blacks. Hypertension. 1999;34(2):315-319.